5 completed, 3 active not recruiting, 1 recruiting. 6 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 3 | 1 | Completed 1 |
Follow Unresectable Gallbladder Carcinoma: new trials by email Literature Review of Unresectable Gallbladder Carcinoma trials Research Report on Unresectable Gallbladder Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Binimetinib, Biopsy Procedure, Biospecimen Collection - Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 17 | 2024-02-09 | 2026-10-19 |
| Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel - Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8 | Phase 3 | Completed | SWOG Cancer Research Network | 452 | 2019-02-07 | 2026-01-12 |
| Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Durvalumab, Guadecitabine - Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type | Phase 1 | Active not recruiting | University of Southern California | 55 | 2018-02-07 | 2026-06-01 |
| Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Ramucirumab - Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 61 | 2015-12-29 | 2023-06-15 |
| Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors Cisplatin, Docetaxel, Gemcitabine Hydrochloride - Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Active not recruiting | University of Southern California | 61 | 2015-09-03 | 2026-04-29 |
| Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7 | Phase 2 | Completed | M.D. Anderson Cancer Center | 62 | 2015-04-02 | 2022-02-02 |
| MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study - Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2011-04-01 | 2016-06-17 |
| Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Erlotinib Hydrochloride, Sorafenib Tosylate - Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2010-04-01 | 2015-06-30 |
Gallbladder Neoplasms (9) · Cholangiocarcinoma (6) · Carcinoma, Hepatocellular (3) · Klatskin Tumor (2) · Pancreatic Neoplasms (2) · Bile Duct Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Squamous Cell Carcinoma of Head and Neck (1)
Biliary Tract Diseases (9) · Biliary Tract Neoplasms (9) · Carcinoma (9) · Digestive System Diseases (9) · Digestive System Neoplasms (9) · Gallbladder Diseases (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms by Site (9) · Neoplasms, Glandular and Epithelial (9) · Adenocarcinoma (8) · Liver Diseases (3) · Liver Neoplasms (3) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2)
1,2-diaminocyclohexaneplatinum II citrate (4) · Cisplatin (4) · Gemcitabine (4) · Platinum (4) · 130-nm albumin-bound paclitaxel (3) · Albumin-Bound Paclitaxel (3) · Taxes (3) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · durvalumab (2) · Biopsy (1) · Disulfides (1) · Docetaxel (1) · Erlotinib Hydrochloride (1) · Fluorouracil (1)
National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (2) · University of Southern California (2) · Ohio State University Comprehensive Cancer Center (1) · SWOG Cancer Research Network (1)
United States (9)
Anthony El-Khoueiry (2) · Anthony El-Khoueiry, MD (1) · Ardaman Shergill (1) · Milind Javle (1) · Rachna Shroff (1) · Rachna T Shroff (1) · Sameek Roychowdhury, MD, PhD (1) · Tanios Bekaii-Saab (1)
P30CA014089 (2), N01CM00070 (1), P30CA016058 (1), U10CA032102 (1), U10CA180821 (1), U10CA180888 (1)